MX2009002054A - Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis. - Google Patents
Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.Info
- Publication number
- MX2009002054A MX2009002054A MX2009002054A MX2009002054A MX2009002054A MX 2009002054 A MX2009002054 A MX 2009002054A MX 2009002054 A MX2009002054 A MX 2009002054A MX 2009002054 A MX2009002054 A MX 2009002054A MX 2009002054 A MX2009002054 A MX 2009002054A
- Authority
- MX
- Mexico
- Prior art keywords
- angiogenesis
- associated diseases
- methods
- treating
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
La invención proporciona métodos para inhibir la angiogénesis en un individuo mediante la administración de una composición (como una proteína contenida en la composición) que comprende el dímero de colchicina o tiocolchicina. La composición está presente en una cantidad efectiva para la inhibición de angiogénesis, pero en algunas modalidades es insuficiente para inducir una citotoxicidad significativa en el individuo. Los métodos descritos aquí son útiles para el tratamiento contra enfermedades asociadas con la angiogénesis, como degeneración macular relacionada con la edad, retinopatía diabética, artritis reumática, psoriasis y cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2006/034365 WO2008027055A1 (en) | 2006-08-31 | 2006-08-31 | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009002054A true MX2009002054A (es) | 2009-05-01 |
Family
ID=37763804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009002054A MX2009002054A (es) | 2006-08-31 | 2006-08-31 | Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2056812A1 (es) |
JP (1) | JP2010502603A (es) |
CN (1) | CN101568332A (es) |
AU (1) | AU2006347740A1 (es) |
BR (1) | BRPI0622006A2 (es) |
CA (1) | CA2662140A1 (es) |
IL (1) | IL197276A0 (es) |
MX (1) | MX2009002054A (es) |
WO (1) | WO2008027055A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
KR101420445B1 (ko) | 2005-08-31 | 2014-07-16 | 아브락시스 바이오사이언스, 엘엘씨 | 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물 |
LT2117520T (lt) | 2006-12-14 | 2018-12-10 | Abraxis Bioscience, Llc | Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną |
DK2481409T3 (en) | 2007-03-07 | 2018-08-06 | Abraxis Bioscience Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
US8927019B2 (en) | 2007-06-01 | 2015-01-06 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
TW201012473A (en) * | 2008-09-22 | 2010-04-01 | Tty Biopharm Co Ltd | Composition of inhibiting pathological angiogenesis |
US20100297243A1 (en) | 2009-04-15 | 2010-11-25 | Desai Neil P | Prion free nanoparticle compositions and methods of making thereof |
CN102802658A (zh) * | 2009-12-21 | 2012-11-28 | 台湾东洋药品工业股份有限公司 | 白细胞衍生趋化因子2于肿瘤细胞内降低肝细胞生长因子受体的磷酸化相关的方法与组合物 |
BR112012024349A2 (pt) | 2010-03-26 | 2016-05-24 | Abraxis Bioscience Llc | métodos de tratamento de carcinoma hepatocelular |
KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
WO2011123395A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of treating cancer |
NZ604031A (en) | 2010-06-04 | 2015-05-29 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
WO2013042684A1 (ja) * | 2011-09-20 | 2013-03-28 | 国立大学法人熊本大学 | リポ蛋白を用いた神経疾患予防・治療剤ならびに神経疾患予防・治療方法 |
RS59322B1 (sr) | 2011-12-14 | 2019-10-31 | Abraxis Bioscience Llc | Upotreba polimernih ekscipijenata za liofilizaciju ili zamrzavanje partikula |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
US10744110B2 (en) | 2013-03-12 | 2020-08-18 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
SG11201507234UA (en) | 2013-03-14 | 2015-10-29 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
EP2924022A1 (en) * | 2014-03-27 | 2015-09-30 | INDENA S.p.A. | Amorphous form of a thiocolchicine derivative |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
KR20230165356A (ko) | 2015-06-29 | 2023-12-05 | 아브락시스 바이오사이언스, 엘엘씨 | 상피양 세포 종양을 치료하는 방법 |
CA3094453A1 (en) | 2018-03-20 | 2019-09-26 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
AU2020375810A1 (en) | 2019-10-28 | 2022-05-12 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1318401B1 (it) * | 2000-03-17 | 2003-08-25 | Indena Spa | Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono. |
DK1585548T3 (en) * | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
KR20050095826A (ko) * | 2002-12-09 | 2005-10-04 | 아메리칸 바이오사이언스, 인크. | 약리학적 물질의 조성물 및 그 전달방법 |
US6825236B2 (en) * | 2003-04-14 | 2004-11-30 | California Pacific Medical Center | Colchicine derivatives |
ITMI20040164A1 (it) * | 2004-02-03 | 2004-05-03 | Indena Spa | Derivati di n.deacetiltiocolchicina loro uso e formulazioni farmaceutiche che li contengono |
EP2301531B1 (en) * | 2005-02-18 | 2018-06-06 | Abraxis BioScience, LLC | Combinations and modes of administration of therapeutic agents and combination therapy |
-
2006
- 2006-08-31 CN CNA2006800561122A patent/CN101568332A/zh active Pending
- 2006-08-31 AU AU2006347740A patent/AU2006347740A1/en not_active Abandoned
- 2006-08-31 CA CA002662140A patent/CA2662140A1/en not_active Abandoned
- 2006-08-31 MX MX2009002054A patent/MX2009002054A/es not_active Application Discontinuation
- 2006-08-31 WO PCT/US2006/034365 patent/WO2008027055A1/en active Application Filing
- 2006-08-31 BR BRPI0622006-1A patent/BRPI0622006A2/pt not_active Application Discontinuation
- 2006-08-31 EP EP06802881A patent/EP2056812A1/en not_active Withdrawn
- 2006-08-31 JP JP2009526583A patent/JP2010502603A/ja active Pending
-
2009
- 2009-02-26 IL IL197276A patent/IL197276A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2056812A1 (en) | 2009-05-13 |
JP2010502603A (ja) | 2010-01-28 |
CN101568332A (zh) | 2009-10-28 |
WO2008027055A1 (en) | 2008-03-06 |
BRPI0622006A2 (pt) | 2011-12-20 |
IL197276A0 (en) | 2009-12-24 |
AU2006347740A1 (en) | 2008-03-06 |
CA2662140A1 (en) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009002054A (es) | Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis. | |
MY155961A (en) | Chemical compounds 251 | |
MY155649A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
MY148246A (en) | Bicyclic amides as kinase inhibitors | |
BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
BRPI0618552B8 (pt) | compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos | |
BRPI0809164B8 (pt) | Composição para administração tópica e composição farmacêutica compreendendo a referida composição | |
CL2008003582A1 (es) | Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash). | |
MX337575B (es) | Compuestos de sulfona y métodos para lafabricación y uso de éstos. | |
IN2012DN02018A (es) | ||
BR112012012918A2 (pt) | agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes. | |
EA201690265A3 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
BRPI0610090A2 (pt) | terapia de combinaÇço compreendendo diaril urÉias para tratar doenÇas | |
AU2012253757A8 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
IN2014MN00139A (es) | ||
MY162903A (en) | Methods of treatment of pancreatic cancer | |
ATE401088T1 (de) | Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs | |
CL2010001260A1 (es) | Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis. | |
UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
CR10099A (es) | Inmunoglobulinas dirigidas contra nogo | |
BRPI0507482A (pt) | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap | |
MX2011008899A (es) | Nuevas orto-aminoamidas para el tratamiento del cancer. | |
MY148893A (en) | Combination of an hdac inhibitor and an antimetabolite | |
TW200740808A (en) | Inhibiteurs de proteines kinases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |